Research on Emerging Medical radionuclides from the X-sections (REMIX): The Accelerator-based Production of 47Sc, 149Tb, 152Tb, 155Tb and 161Tb

The REMIX project is focused on the cyclotron-based production of Sc-47, Tb-149, Tb-152, Tb-155 and Tb-161 radionuclides, whose decay characteristics make them suitable for medical applications. This work will outline the main results achieved withing the REMIX collaboration, that is organized in the following Work Packages (WP): WP1. Target manufacturing (Ti-49, Ti-50 and (Gd2O3)-Gd-155) and characterization; WP2. Nuclear cross section (XS) measurements with Ti-49 and Ti-50 targets for Sc-47 production; WP3. Nuclear XS measurements with Dy-nat, Tb-159 and Eu-nat targets for Tb-xx production; WP4. Nuclear XS modeling for Sc-47 and Tb-155 production; WP5. Dosimetric calculations for Sc-47- and Tb-xx-labelled radiopharmaceuticals; WP6. Tb-155 Thick Target Yield (TTY) measurements; WP7. Apparatus design and realization for irradiation tests with the LARAMED beamline. Since the LARAMED bunkers and ancillary laboratories are currently under completion at the INFN-LNL, the nuclear XS experiments are carried out in collaboration with the GIP ARRONAX facility (Saint-Herblain, France) and the Thick Target Yield (TTY) measurements are performed at the Sacro Cuore Don Calabria hospital (SCDCh, Negrar, Verona, Italy).